Glaukos Corp is primarily active in the medical devices industry.

The main competitors of Glaukos Corp in the market are Alcon Inc., Bausch Health Companies Inc., and Johnson & Johnson Vision.

Glaukos Corp is a renowned medical technology company specializing in developing and commercializing innovative products for glaucoma treatment. Founded in 1998, Glaukos Corp has a rich history of revolutionizing the field of ophthalmology. Since its inception, the company has introduced groundbreaking glaucoma therapies, including the iStent®, the world's first MIGS (Micro-Invasive Glaucoma Surgery) device. Glaukos Corp is committed to providing sustainable solutions for patients suffering from glaucoma, a leading cause of blindness. With its cutting-edge technologies, the company has transformed glaucoma management, offering safer and effective treatment options. Glaukos Corp continues to shape the future of glaucoma care through its dedication to innovation and improving patients' lives.

Since its establishment, Glaukos Corp has achieved several noteworthy milestones. The company's pioneering technologies have revolutionized the field of ophthalmic surgery, offering innovative solutions for glaucoma treatment. Glaukos Corp's breakthrough product, iStent®, became the first-ever micro-invasive glaucoma surgery device approved by the FDA. This milestone marked a major advancement in improving the lives of glaucoma patients worldwide. Additionally, Glaukos Corp has expanded its product portfolio, introducing iStent inject® and iStent inject®W, further solidifying the company's commitment to providing effective and minimally invasive solutions for reducing intraocular pressure. With these accomplishments, Glaukos Corp continues to lead the way in the advancement of glaucoma treatment.

Glaukos Corp is primarily present in the United States with headquarters located in San Clemente, California.

Glaukos Corp represents a set of core values and a corporate philosophy that drives its operations. The company is committed to advancing the field of ophthalmic medical technology and improving the lives of patients with glaucoma. Glaukos Corp follows a patient-centric approach, focusing on developing innovative and minimally invasive treatment options for the eye disease. With a strong dedication to research and development, Glaukos Corp aims to provide effective and sustainable therapies. The company's vision is to become the global leader in micro-scale devices for glaucoma, offering groundbreaking solutions to enhance patients' quality of life. Through its unwavering commitment and innovative spirit, Glaukos Corp continues to revolutionize the way glaucoma is treated.

Analysts currently set an average price target of 135.37 USD for the Glaukos stock (median: 133.11 USD), implying -26.6 % versus the latest price. The consensus is based on 22 analyst ratings.

Glaukos Analyst Price Targets 2026

22 analysts currently rate the Glaukos stock: 19 recommend buying, 2 holding and 1 selling. For 2026, analysts expect Glaukos to generate revenue of 690.70 M USD and earnings per share of -0.29 USD.

Glaukos Analyst Price Targets 2026

Converted at the current exchange rate, the Glaukos share trades at 159.47 EUR (184.53 USD).

The Glaukos share (GKOS) is listed on 4 stock exchanges, including: NYSE (GKOS), Frankfurt (6GJ.F), München (6GJ.MU), Düsseldorf (6GJ.DU).

Glaukos Corp is a publicly traded company (NYSE: GKOS) specializing in the development, manufacturing, and marketing of ophthalmological devices and products. The company was founded in 1998 and is headquartered in San Clemente, California. Glaukos Corp has several divisions, including the iStent system, Hydrus Microstent, iDose system, as well as individual and accessory products. The iStent system is the first FDA-approved microimplant for use in patients with open-angle glaucoma (OWG). The iStent injector system is an injector that allows for easy placement of the iStent into the Schlemm's canal. The Hydrus Microstent system is a microscopic stent that is inserted into the Schlemm's canal to improve blood flow in the eyes. The iDose system is a drug-delivery implant used for continuous and precise administration of ophthalmic medications. Glaukos also offers individual products such as the TRAB 360 implant needle and the iStent bayonet insertion device. Accessory products such as gonioscopy lenses, lid speculum, microstents, and trabeculectomy kits complement the offering. Glaukos Corp's business model is based on addressing market niches that have not been sufficiently treated by conventional methods. With its products, Glaukos aims to improve the safety and effectiveness of eye surgeries while meeting the needs of physicians and patients. To support its expansion, Glaukos has also formed strategic partnerships with other companies in the industry. In 2018, the company announced a collaboration with Santen Pharmaceutical Co., Ltd., a leading company in the ophthalmic industry. This collaboration includes the development of drug products and devices. Another important aspect of Glaukos' business model is investment in research and development. The company is strongly committed to innovation and has made significant investments in developing new products in recent years. In summary, Glaukos Corp offers a wide range of ophthalmological products and systems. The company focuses on closing gaps in the treatment of eye diseases by developing and distributing innovative solutions worldwide. Through its innovative technology and strong commitment to research and development, the company has established itself as a market leader in its field.

The expected revenue of Glaukos is 690.70 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Glaukos is -16.68 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Glaukos is currently -636.27. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Glaukos stock.

The price-to-sales ratio (P/S) of Glaukos is currently 15.36. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Glaukos stock.

The Eulerpool Quality Score for Glaukos is 3/10.

The ISIN of Glaukos is US3773221029. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Glaukos is A14VCK. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Glaukos is GKOS. The ticker symbol is used to trade Glaukos shares on the stock exchange.

Glaukos paid dividends every year for the past 0 years.

Glaukos is assigned to the 'Health' sector.

The dividends of Glaukos are distributed in USD.